Beam Therapeutics Inc
General ticker "BEAM" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.3B
Beam Therapeutics Inc follows the US Stock Market performance with the rate: 5.6%.
Estimated limits based on current volatility of 4.3%: low 26.80$, high 29.19$
Factors to consider:
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [18.56$, 40.00$]
- 2024-12-30 to 2025-12-30 estimated range: [19.93$, 41.55$]
Financial Metrics affecting the BEAM estimates:
- Negative: Non-GAAP EPS, $ of -1.90 <= 0.10
- Negative: Operating profit margin, % of -31.85 <= 1.03
- Negative: Operating cash flow per share per price, % of -6.36 <= 2.35
- Negative: negative Net income
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
- Negative: Industry earnings per price (median), % of -26.04 <= 1.31
Short-term BEAM quotes
Long-term BEAM plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $51.84MM | $60.92MM | $377.71MM |
| Operating Expenses | $444.31MM | $399.40MM | $554.19MM |
| Operating Income | $-392.46MM | $-338.48MM | $-176.49MM |
| Non-Operating Income | $21.83MM | $78.30MM | $45.32MM |
| Interest Expense | $0.01MM | $15.30MM | $0.00MM |
| R&D Expense | $387.09MM | $311.59MM | $437.38MM |
| Income(Loss) | $-370.64MM | $-260.18MM | $-131.16MM |
| Taxes | $0.00MM | $3.41MM | $1.37MM |
| Profit(Loss) | $-370.64MM | $-263.59MM | $-132.53MM |
| Stockholders Equity | $826.74MM | $733.47MM | $981.33MM |
| Inventory | $607.36MM | $0.00MM | $0.00MM |
| Assets | $1,474.45MM | $1,341.71MM | $1,459.71MM |
| Operating Cash Flow | $-66.27MM | $22.53MM | $-149.19MM |
| Capital expenditure | $46.81MM | $48.95MM | $33.73MM |
| Investing Cash Flow | $-294.14MM | $-461.34MM | $71.84MM |
| Financing Cash Flow | $756.14MM | $111.59MM | $276.45MM |
| Earnings Per Share* | $-5.31 | $-3.76 | $-1.72 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.